Clinicopathological characteristics of HER2 low expression gastric adenocarcinoma
10.13315/j.cnki.cjcep.2025.03.009
- VernacularTitle:HER2低表达胃腺癌临床病理特征
- Author:
Yilin MU
1
;
Dongliang LIN
;
Shuchao ZHAO
;
Hailei SHI
;
Hui HE
;
Haiyan ZHANG
;
Xiaoming XING
Author Information
1. 青岛大学基础医学院,青岛 266071
- Publication Type:Journal Article
- Keywords:
gastric neoplasms;
adenocarcinoma;
HER2 low expression;
clinicopathological characteristics;
prognosis
- From:
Chinese Journal of Clinical and Experimental Pathology
2025;41(3):334-339
- CountryChina
- Language:Chinese
-
Abstract:
Purpose To explore the relationship between the proportion of HER2 low expression and clinicopatho-logical characteristics of gastric adenocarcinoma patients.Methods Clinical data from 3 779 gastric adenocarcinoma patients who underwent radical resection were collected.HER2 expression was categorized using immunohistochemistry combined with FISH,and the clinicopathological characteristics and prognosis of HER2 low expression gastric adeno-carcinoma patients were analyzed.Results Among the 3 779 gastric adenocarcinoma cases,1 251 cases(33.10％)showed HER2 low expression.Compared with HER2 negative expression,HER2 low expression patients were more likely to be older males,present with well-differentiated Lauren's intestinal-type adenocarcinoma,and have less nerve invasion.Furthermore,compared to HER2 negative expression,they showed higher Ki67 proliferation index and more advanced clinical stage.Meanwhile,compared with patients with HER2 over expression,those with low HER2 expres-sion were more likely to be younger females,present with well-differentiated Lauren's diffuse-type adenocarcinoma,and have more nerve invasion.Furthermore,compared to HER2 over expression,they showed lower Ki67 proliferation index and more advanced clinical stage.There was no significant difference in prognosis between HER2 low expression,HER2 negative,and HER2 over expression groups.Conclusion HER2 low expression have a relatively large propor-tion in gastric adenocarcinoma patients,and HER2-targeted antibody-drug conjugates may provide an effective treatment option for these patients with HER2 low expression.
